SEC Form 4 · accession 0001209191-15-067124
NOVAVAX INC · NVAX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory M Glenn
Officer — SVP, Research and Development
Period of report
Aug 18, 2015
Accepted (ET)
Aug 20, 2015 · 5:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001000694
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 18, 2015 | M | 15,000 | $2.11 | A | 16,158 | D | |
| Common StockF1 | Aug 18, 2015 | S | 15,000 | $13.5162 | D | 1,158 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F2 | $2.11 | Aug 18, 2015 | M | 15,000 | D | — | Jul 1, 2020 | Common Stock | 15,000 | 335,000 | D |
Explanation of responses
- F1The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.46 to $13.58, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- F2The 15,000 shares exercised on 08/18/2015 pursuant to this stock option vested on 07/01/2011.